Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effect of the basal-bolus detemir-aspart insulin regimen coupled with continuous glucose monitoring (CGM) on glycemic control in hemodialyzed patients with diabetes

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Europeen d'Etude du Diabete
• Collaborators: Abbott; Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• age between 18 and 83 years

• diagnosis of type 1 or type 2 diabetes

• treatment with insulin injections or oral hypoglycemic agents

• HbA1c ≥ 7% (i.e., 53 mmol/mol)

• on hemodialysis for more than three months

Exclusion Criteria:

• unstable anemia or blood transfusions within the two months prior to the beginning of the study

• a life expectancy of less than 1 year

• chronic inflammatory disease

• evolutive cancer requiring steroid treatment, chemotherapy, radiotherapy, or programmed surgery

• noncompliant patients